Enzene Biosciences Ltd.

Quick facts

Phase 3 pipeline

• ENZ215
  ENZ215 is an investigational therapeutic targeting a specific molecular pathway in early-to-mid stage clinical development by Enzene Biosciences.

Phase 1 pipeline

• EU Sourced Prolia
• US Sourced Prolia

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Enzene Biosciences Ltd. portfolio CI brief
• Enzene Biosciences Ltd. pipeline updates RSS